Author:
Thorbjornsdottir Perla,Thorgeirsson Gudmundur,Kotwal Girish J.,Arason Gudmundur Johann
Reference252 articles.
1. Ahearn, J. M. & Fearon, D. T. 1989 Structure and function of the complement receptors, CR1 (CD35) and CR2 (CD21). Adv Immunol 46, 183–219.
2. Al-Mohanna, F., Parhar, R. & Kotwal, G. J. 2001 Vaccinia virus complement control protein is capable of protecting xenoendothelial cells from antibody binding and killing by human complement and cytotoxic cells. Transplantation 71, 796–801.
3. Amsterdam, E. A., Stahl, G. L., Pan, H. L., Rendig, S. V., Fletcher, M. P. & Longhurst, J. C. 1995 Limitation of reperfusion injury by a monoclonal antibody to C5a during myocardial infarction in pigs. Am J Physiol 268, H448–57.
4. Anderson, J. B., Smith, S. A., van Wijk, R., Chien, S. & Kotwal, G. J. 2002 Vaccinia virus complement control protein ameliorates hyperacute xenorejection by inhibiting xenoantibody binding. Transplant Proc 34, 3277–81.
5. Anderson, J. B., Smith, S. A., van Wijk, R., Chien, S. & Kotwal, G. J. 2003 Vaccinia virus complement control protein inhibits hyperacute xenorejection in a guinea pig-to-rat heterotopic cervical cardiac xenograft model by blocking both xenoantibody binding and complement pathway activation. Transpl Immunol 11, 129–35.